“Kangwanda” completed a new round of financing to accelerate the research and development of oncolytic virus pipeline products

Visit the original URL

Chuangyebang was informed that recently, Kangwanda, an oncolytic virus drug developer, announced the completion of a new round of financing and the introduction of strategic partners. This round of financing was jointly participated by Dongheng Industrial Group, Huafang Capital and Blue Mountain Investment.

It is understood that the funds obtained from this round of financing are mainly used for the clinical research of Convanda’s new generation of oncolytic virus pipeline products and the development of follow-up guided virus products.

The investors said that Dr. Hu Fang, the founder of Kangwanda Pharmaceutical, as a pioneer in the field of oncolytic virus drugs, has unique research and development ideas and extensive research and development ideas for the clinical application of oncolytic viruses and the druggability of oncolytic viruses. Industry resources. Kangwanda has a professional and pragmatic R&D team and innovative ideas, and has developed a series of oncolytic virus vector platforms. The comprehensive deployment of oncolytic viruses and related anti-tumor immunotherapy in the biotechnology track will better promote the clinical application of oncolytic viruses.

Hangzhou Kangwanda Pharmaceutical Technology Co., Ltd. was established in February 2012. It has been committed to the research and development of oncolytic virus innovative drugs and therapies under the theory of tumor system immunity. The founder of the company, Dr. Hu Fang, led the team to complete the world’s first oncolytic virus drug. “Ankerui” research and development and listing.

As a bio-innovative drug company in China with multiple viral technology platforms such as oncolytic vaccinia virus and oncolytic adenovirus, Kangwanda currently has 7 oncolytic virus pipeline projects and more than 80 patents (applications) (13 authorized patents). ), of which the first domestic self-developed oncolytic vaccinia virus V01 project is expected to start clinical research within this year.

media coverage

100 million euros in the venture capital investment community
Related events

This article is reprinted from: https://readhub.cn/topic/8icsm5XF5gg
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.